Fertab

Quick links to important sections

Fertab

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fertab

Property Description
Active ingredient Clomifene Citrate (Clomifene)
Form Tablet
Pharmacological class Selective Estrogen Receptor Modulator (SERM)
Common use Ovulation induction
Origin Synthetic, nonsteroidal compound

What Type of Medicine is Fertab?

Fertab is a prescription-only pharmaceutical preparation containing the active ingredient Clomifene Citrate, which belongs to the class of Selective Estrogen Receptor Modulators (SERMs). This classification is clinically recognized for its unique mechanism that selectively affects estrogen receptors. As a fertility agent, Clomifene is used to cause ovulation in women who do not produce eggs but wish to become pregnant. The key takeaway for patients is that this medication assists the reproductive system in performing the necessary biological step for conception.

Clomifene is classified chemically as a nonsteroidal compound, distinguishing its structure from that of natural steroid hormones. Fertab is manufactured as a single-ingredient product delivered in tablet form for simple oral administration, providing a non-invasive option for hormonal modulation.

The Active Component: Clomifene Citrate Composition

The essential active substance within Fertab is Clomifene Citrate (INN: Clomifene), acting as the core chemical entity. This synthetic derivative is manufactured with standard pharmaceutical excipients necessary for the tablet dosage form. The product's identity is defined entirely by this single active ingredient, which is known to be administered as a racemic mixture of the geometric isomers, zuclomiphene and enclomiphene.

Clomiphene’s role in promoting ovulation occurs via interaction with hypothalamic estrogen receptors, illustrating its foundational use in fertility treatment. This supports the fact that the drug works by influencing the brain's hormonal signals rather than acting directly on the ovaries.

General Purpose: Why is Fertab Used?

Fertab’s general purpose is to promote the development of an ovarian follicle and trigger ovulation in women who may not be ovulating on their own. The medicine achieves this by temporarily creating a perception of low estrogen levels in the brain's control centers, thereby initiating a natural surge of gonadotropin hormones. This unique mechanism bypasses the primary hormonal imbalance to encourage the ovaries to release a mature egg, serving the overarching goal of supporting reproductive health. A typical, neutral use scenario involves managing anovulatory infertility in women desiring pregnancy, aiming to establish a reliable, timed ovulatory cycle.

Regulatory References

  1. Clomiphene: MedlinePlus Drug Information
  2. NIH MedlinePlus

What side effects are possible with Fertab?

Possible Side Effects and Safety Information

The safety profile for Fertab (Clomifene Citrate) is strictly defined by government regulatory documents, which categorize adverse reactions based on their officially documented frequency and the affected body system. The medicine’s use is associated with specific safety constraints and time-related patterns, particularly concerning the female reproductive system.


Official Adverse Reaction Categories

Adverse effects are categorized by frequency in official labeling:

  • Very Common: Hot flushes are the most frequently reported adverse reaction.
  • Common: Adverse effects reported by regulatory authorities as common include headache, ovarian enlargement, abdominal/pelvic discomfort, nausea, vomiting, and transient visual symptoms (e.g., blurred vision).
  • Uncommon: Reactions such as breast discomfort, intermenstrual spotting or bleeding, and reversible hair loss are classified as uncommon.

Serious Adverse Reactions and Safety Constraints

The regulatory profile identifies specific, rare, but clinically significant safety concerns. Severe Ovarian Hyperstimulation Syndrome (OHSS) and ectopic pregnancy are officially documented serious adverse reactions. Ovarian enlargement and OHSS typically occur during or shortly after the course of treatment. The regulatory label notes that visual symptoms, though generally reversible, may become prolonged after cessation of therapy.

Use of Fertab is formally restricted by regulatory agencies in individuals with pre-existing conditions. It is contraindicated in patients with known liver disease or a history of liver dysfunction, as well as in cases of undiagnosed abnormal uterine bleeding or the presence of most ovarian cysts (excluding those associated with PCOS).

Overdose and Emergency Response

Overdose Manifestations and Severe Risks

An overdose of Fertab (Clomifene Citrate) is documented in regulatory sources by a cluster of recognizable clinical signs. These manifestations include common gastrointestinal upset, such as nausea and vomiting, and vasomotor flushes. More specific signs involve abdominal or pelvic pain and ovarian enlargement. Of particular concern are visual disturbances, which may include blurred vision or the appearance of scintillating scotomata (flashes or spots). High doses are formally associated with the critical risk of developing Severe Ovarian Hyperstimulation Syndrome (OHSS), a condition classified as potentially life-threatening. Severe OHSS symptoms can involve complications such as pulmonary oedema or renal failure. Furthermore, regulatory information notes that visual disturbances may become prolonged and potentially irreversible.

Emergency Actions Mandated by Regulators

Governmental prescribing information strictly mandates that users seek emergency medical attention immediately upon suspected overdose. Urgent medical help is required for severe manifestations, including the onset of severe OHSS symptoms—such as rapid weight gain, trouble breathing, or rapid heart rate—or if the individual has collapsed or cannot be awakened. If any unusual visual symptoms occur, regulatory documents require the medicine to be discontinued immediately. Management, as described in official documents, includes the application of appropriate supportive measures and procedural steps like gastrointestinal decontamination. Regulatory information confirms that no specific antidote is known for Clomifene Citrate overdose.

Therapeutic Uses of Fertab

What Fertab Treats: Main Uses and Benefits

Fertab is a medication primarily prescribed to address certain types of infertility in women. The medicine is used for the Treatment of ovulatory dysfunction in women wishing to become pregnant. In this capacity, it supports women who experience symptoms related to systemic imbalance and reproductive challenges.

The medication is applicable across conditions characterized by periods of heightened symptoms, involving episodic or fluctuating manifestations. It is relevant in clinical settings that involve acute or unstable symptom patterns where short-term symptomatic assistance is needed. Fertab is often used to help with symptoms that create noticeable functional strain.

Assisting with Functional Stability

Fertab provides supportive relief that helps patients cope more steadily with symptom fluctuations and difficult episodes. The medicine assists with maintaining functional stability by easing distress and contributing to the overall symptom burden. It is applied in situations involving certain distressing symptoms and supports patients during episodes of heightened discomfort.

Quick Fact: Support for Fluctuating Symptoms
Fertab is commonly used to help with symptom clusters that may become intense or disruptive.

Regulatory References

  1. Saudi Food and Drug Authority (SFDA) Drug Information System

Eligibility and Restrictions for Use

Fertab (Clomifene Citrate) is strictly limited to adult women of reproductive age with demonstrated ovulatory dysfunction who are desiring pregnancy. Eligibility is defined by formal regulatory criteria, including specific exclusions.

Populations for Whom Use is Contraindicated

Use is absolutely prohibited for patients with the following conditions, as stated in official labeling:

Contraindicated Condition Eligibility Status
Pregnancy Contraindicated (must be excluded before each course)
Liver Disease / History of Liver Dysfunction Contraindicated
Abnormal Uterine Bleeding of undetermined cause Contraindicated
Ovarian Cysts or enlargement (not due to PCOS) Contraindicated
Uncontrolled Endocrine Conditions (e.g., thyroid, adrenal) Contraindicated

Age and Duration Restrictions

  • Pediatric/Adolescent Use: Not generally recommended, as the indication focuses on adult reproductive issues.
  • Geriatric Use (ge 65): Safety and effectiveness are not established in this age group.
  • Treatment Duration: Long-term cyclic therapy is not recommended; regulators caution against use beyond a total of about six cycles (including three ovulatory cycles).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fertab (Clomifene Citrate) has an officially documented interaction profile characterized by the absence of specific warnings regarding drug-drug, drug-food, or drug-substance interactions in its primary regulatory labeling.

Regulatory authorities, including the US Food and Drug Administration (FDA) and European agencies, typically include a dedicated section for interactions in the prescribing information, but this section for clomifene does not list any specific co-administered medicinal products that require adjustment or prohibition.

Official Regulatory Interaction Profile

Interaction Category Regulatory Status
Specific Medicinal Products No specific interacting medicines are explicitly listed.
Metabolic Mechanisms No specific pharmacokinetic interactions (e.g., CYP enzyme effects) are formally documented.
Timing Requirements No mandatory timing rules are documented for separating administration.
Food, Alcohol, or Supplements No specific interactions with food, alcohol, or herbal supplements are officially documented.

Interaction-Related Constraints

There are no explicit restrictions documented in the official regulatory prescribing information mandating that Fertab must not be co-administered with specific medicinal products. This structure indicates that major regulatory bodies have not identified clinically significant interactions that necessitate specific, label-based restrictions or contraindications within the dedicated interaction section. The medicine's profile does not include formal statements regarding pharmacodynamic or transporter-mediated interactions.

Mechanism of Action

Fertab is classified as a nitrogen-containing bisphosphonate that regulates bone metabolism. It exhibits a high affinity for bone mineral, resulting in its accumulation preferentially at sites of active remodeling. Fertab’s primary biological target is the osteoclast, the cell type responsible for bone resorption.

Once internalized by the osteoclast during the resorption process, the compound acts as an inhibitor of the enzyme farnesyl pyrophosphate synthase (FPPS) within the mevalonate pathway. This enzymatic inhibition halts the biosynthesis of crucial isoprenoid lipids, specifically farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). The absence of these lipids prevents the post-translational prenylation of small GTPases (such as Rac and Rho) essential for osteoclast function and cytoskeletal integrity.

This molecular cascade disrupts the osteoclast's ruffled border and impairs its capacity for adhesion and acid secretion, leading ultimately to osteoclast apoptosis (programmed cell death). The resulting system-level physiological consequence is a reduction in bone turnover and bone resorption activity.

Dosage and Administration Information

How to Use Fertab: Official Administration Guidelines

Fertab (Clomifene Citrate) is strictly administered through the oral route as a tablet, following a highly structured, cyclic schedule. Its use is standardized around specific dosage amounts and limited duration, ensuring consistency in its clinical application.


Core Dosage and Scheduling Protocol

The medicine is taken once daily for five consecutive days per course. The administration is initiated relative to the menstrual cycle:

  • Initial Dose: The regimen typically begins with a dose of 50 mg taken once daily for five days.
  • Cycle Timing: The first course is generally started on or about the fifth day of the menstrual cycle, if natural or induced bleeding has occurred. If a patient is not experiencing recent uterine bleeding, the course may be initiated at any time.
  • Dose Escalation: If ovulation does not occur after the first 50 mg course, the dose may be increased to 100 mg once daily for five days in subsequent courses. The maximum daily dose for any course should not exceed 100 mg.

These dosing rules serve as the standard parameters for the clinical use of this medication.


Use Patterns and Constraints

The usage of Fertab is defined by strict procedural limits on duration and timing between courses:

  • Course Interval: Following the completion of a five-day course, subsequent courses must not be started until at least 30 days have passed, and only after ensuring pregnancy has not occurred.
  • Total Duration Limit: Clinical guidelines advise limiting the total number of treatment cycles; typically, usage is restricted to approximately six cycles in total.
  • Special Population: For patients with increased sensitivity, such as those diagnosed with Polycystic Ovary Syndrome (PCOS), treatment is initiated at the lowest effective dose. These procedural constraints are in place to standardize the use of the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Fertab

Evidence for Use in Ovulatory Dysfunction and Infertility

The research on Fertab for ovulation induction and the clinical context of anovulatory infertility has primarily consisted of Randomized Controlled Trials (RCTs) and supporting Systematic Reviews. These studies were used in research exploring how functional balance may change over a defined time period. The main populations evaluated in this research were women diagnosed with chronic anovulation, including those with conditions such as Polycystic Ovary Syndrome (PCOS).

In these studies, research examined outcomes related to systemic or functional imbalance. Specifically, researchers monitored the Ovulation Rate (confirmed through hormones and ultrasound), the Clinical Pregnancy Rate, and the Live Birth Rate. The findings describe patterns observed in the studies that confirmed ovulation was reported. However, the outcomes related to clinical pregnancy and live birth rates were measured less frequently than the ovulation rate itself.

Research Context for Hormonal Shifts in Men

The active substance in Fertab has also been studied in the context of hormonal markers in men. Research examined temporary physiological imbalance in men seeking fertility treatment, including those diagnosed with secondary hypogonadism or specific forms of Azoospermia. These studies involved various trial designs, including controlled trials and prospective studies.

Studies explored the observed effects by measuring outcomes related to systemic or functional imbalance, such as changes in Serum Testosterone, Luteinizing Hormone (LH), and Follicle-Stimulating Hormone (FSH) levels. Findings indicate that changes in these hormonal biomarkers were measured during the study period. However, the evidence supporting clinical endpoints, such as achieving a live birth, remains limited for this use.

What Remains Uncertain About the Research for Fertab

One key limitation is the widely reported difference between the frequency of confirmed ovulation and the final live birth rates measured in many studies. The research does not clarify the reason for this gap. Furthermore, long-term effects are not fully established, as follow-up durations were limited in the primary research. Data for certain groups, such as those with unexplained infertility challenges, remain insufficient.

Key Studies & References

  1. Fertility Problems: Assessment and Treatment (NICE Guideline NG126)
  2. Saudi Food and Drug Authority (SFDA) Drug Information System - Clomifene Drug ID 4699

Frequently Asked Questions (FAQ)

Common questions about Fertab (FAQ)

Q: What happens if I forget to take Fertab one day?

Regulatory guidance suggests that if a dose is missed, contacting a healthcare provider is suggested for specific instructions. Patient information generally states that taking extra medication to make up for a missed dose, or doubling up doses, should be avoided.


Q: Is Fertab available without a prescription?

According to official regulatory classifications, Fertab (Clomiphene Citrate) is designated as a prescription-only medicine in most regions, meaning it requires a prescription from a licensed healthcare provider.


Q: Do I need any special monitoring or tests while on Fertab?

Regulatory documents state that monitoring procedures, such as a pelvic examination before starting treatment and before each subsequent course, are described to check for potential ovarian enlargement or cyst formation.


Q: Is it normal to feel tired or dizzy when taking Fertab?

Dizziness and fatigue (tiredness) are included in the safety documentation among the reported adverse effects. These effects are typically listed in the less common or frequency not reported categories.


Q: Can I take vitamins or supplements while using Fertab?

The official regulatory labeling for Fertab does not explicitly list specific vitamins or non-herbal supplements that are prohibited. However, patients are generally advised to discuss all co-administered substances, including supplements, with a healthcare provider.


Q: Will Fertab interfere with my sleep schedule?

Trouble sleeping, or insomnia, and nervous tension are listed among the reported adverse effects in the safety documentation. These effects are generally classified as less common.


Q: Does Fertab have any official warnings or black box warnings?

Regulatory documents contain a 'Warnings and Precautions' section that highlights serious safety issues. This includes the risk of Severe Ovarian Hyperstimulation Syndrome (OHSS), which is a serious adverse reaction documented in the official labeling.


Q: How soon after stopping Fertab does it leave my system?

Pharmacokinetic data from official sources indicates that the medicine has an elimination half-life of approximately five to seven days. The substance is excreted primarily via the feces over time.


Q: How long does it usually take for Fertab to start working?

Studies and official information indicate that the biological effects leading to ovulation are generally expected to occur within 5 to 10 days following the completion of the five-day treatment course.


Q: Is Fertab used when trying to conceive?

The medicine's official indication is for use in women desiring pregnancy due to ovulatory dysfunction. However, official information states that its use is contraindicated if pregnancy is already confirmed, and appropriate tests are required before each course begins.


Q: Can men use Fertab, or is it only for women?

The FDA-approved indication for Fertab is specifically for treating ovulatory dysfunction in women who are seeking pregnancy. Its use in men is considered outside of this labeled indication.


Q: Does Fertab interact with common pain relievers like ibuprofen?

The official regulatory labeling for this medicine is characterized by the absence of specific warnings regarding drug-drug interactions. It does not explicitly list common pain relievers like ibuprofen as specific interacting medicines that require adjustment.


Q: What kind of studies have been done on the long-term use of Fertab?

Regulatory documents advise limiting the total number of treatment cycles. They caution that prolonged use, generally defined as beyond 12 cycles, has been associated with a possible increased risk of certain ovarian tumors in some studies.


Q: Can I drink coffee while taking Fertab?

Official regulatory labeling does not explicitly document any specific interactions or mandatory timing rules regarding the consumption of coffee or food.


Q: Is Fertab the same ingredient as [Another Formulation Name]?

Fertab contains the active ingredient Clomiphene Citrate. Different pharmaceutical products may utilize this same active substance, but specific formulations and inactive ingredients can vary by manufacturer and brand name.


Q: What if I experience unusual mood changes while taking Fertab?

Mood changes, anxiety, irritability, and depression are listed among the reported adverse effects in post-marketing reports for this medicine. It is standard practice for patients to discuss any bothersome or persistent side effects with a healthcare provider.


Q: Is it true that Fertab can cause weight gain?

Weight gain and weight loss are both listed in the safety documentation among the reported adverse effects in the post-marketing or frequency not reported categories.


Q: Are there restrictions on foods I can eat while taking Fertab?

Official regulatory labeling does not explicitly document any specific restrictions or mandatory timing rules regarding food co-administration. The labeling does not specify any restrictions, suggesting administration is generally possible without regard to meals.


Q: What age range is Fertab typically prescribed for?

The medicine is officially indicated for use in adult women of reproductive age who are experiencing ovulatory dysfunction. Its use is not generally recommended or established for pediatric and geriatric populations.


Q: Can Fertab affect blood pressure?

Post-marketing reports have included cardiovascular events such as hypertension (high blood pressure) and hypotension among the reported adverse effects in the safety documentation.


Q: Does Fertab interact with birth control pills?

The official regulatory labeling does not explicitly list oral contraceptives as specific interacting medicines that require adjustment or prohibition. The medicine is intended for use in situations where a patient is trying to conceive and therefore is typically not used at the same time as hormonal birth control.


Q: What is the pregnancy risk category for Fertab?

Fertab is contraindicated for use in pregnancy. In regions that use a categorization system, it has historically been classified in the category associated with absolute contraindication during pregnancy, such as Pregnancy Category X or B3.


Q: Where can I find the official patient information leaflet for Fertab?

Official patient information leaflets (PILs) and prescribing information documents are made available through government-run authority websites, such as the FDA's DailyMed and other national health portals.


Q: Can Fertab interact with herbal supplements like St. John's Wort?

The official regulatory labeling does not explicitly list St. John's Wort or other specific herbal supplements as interacting substances that require adjustment or prohibition.


Q: What should I do if a side effect doesn't go away?

Official patient information generally suggests contacting a healthcare provider for advice. This is recommended if any adverse effect persists, becomes bothersome, or if you have any questions regarding your condition.


Q: What happens if I take too much Fertab?

Regulatory documents describing overdosage report symptoms such as nausea, vomiting, visual disturbances (blurring), and abdominal or pelvic pain, which may be due to ovarian enlargement. Seeking medical attention is necessary if symptoms of overdosage are experienced.


Q: Are there documented cases of allergic reactions to Fertab?

Post-marketing safety reports have documented rare cases of allergic reactions, including skin rash, hives (urticaria), and swelling of the face, lips, or tongue (angioedema).


Q: Is there any difference between taking Fertab in the morning versus the evening?

Official prescribing information defines the medicine as being taken once daily for five days. The labeling does not generally specify or mandate a particular time of day (morning or evening) for administration.

How should Fertab be stored and disposed of?

How to Store and Dispose of Fertab (Clomifene Citrate)

The storage and disposal of Fertab must strictly follow official regulatory requirements to ensure product stability and household safety.

Storage Requirements

Fertab must be stored at a controlled room temperature, typically defined as 15 C to 30 C (59 F to 86 F), or below 25 C in some regions. The tablets must be kept from freezing and protected from heat, moisture, and light by remaining in their original, tightly closed container.

Safety and Disposal

It is an explicit regulatory requirement to keep this medicine out of the sight and reach of children.

Expired or unused Fertab must not be discarded with household garbage or wastewater. Official guidance directs patients to ask a pharmacist for instructions on the correct disposal of unused medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fertab found in:

A-Z Index: